Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Capsipod is a topical podological formulation developed by Epitech for the management of foot skin and nail disorders. It utilizes ALIAmide (Autacoid Local Inflammation Antagonism) technology, featuring the active ingredients adelmidrol and trans-traumatic acid. Adelmidrol, a synthetic analogue of the endogenous fatty acid amide palmitoylethanolamide (PEA), acts by modulating mast cell degranulation and downregulating dermo-epidermal hyper-reactivity, primarily through the activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha). Trans-traumatic acid is included to support the restoration of the skin barrier and promote tissue repair. Capsipod is marketed as a medical device in the European Union for the treatment of localized skin reactivity, inflammation, and pain associated with conditions such as podological dermatitis and nail dystrophies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Capsipod.